ProCE Banner Activity

Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer

Slideset

Download this focused slideset on incorporating adjuvant CDK4/6 inhibitors into the treatment of patients with HR-positive/HER2-negative early-stage breast cancer, including patient selection, toxicity management, and adherence considerations.

Released: May 01, 2024

Expiration: April 30, 2025

Share

Faculty

Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner